Johnson & Johnson
JNJToday
+0.93%
5 Days
+5.61%
1 Month
+17.19%
6 Months
+40.68%
Year to Date
+15.97%
1 Year
+56.34%
TradingKey Stock Score of Johnson & Johnson
Currency: USD Updated: 2026-02-06Key Insights
Johnson & Johnson's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 25 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 230.53.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Johnson & Johnson's Score
Support & Resistance
Score Analysis
Media Coverage
Johnson & Johnson Highlights
Johnson & Johnson is an American multinational corporation specializing in pharmaceuticals, biotechnology, and medical technologies, headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange (NYSE:JNJ). Its common stock is part of the Dow Jones Industrial Average, and the company is ranked No. 42 on the 2024 Fortune 500 list of the largest corporations in the United States. In 2024, it was ranked 45th on the Forbes Global 2000 list. Johnson & Johnson employs approximately 138,000 individuals globally, led by its current chairman and CEO, Joaquin Duato.
Founded in 1886 by three brothers—Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson—the company initially focused on selling ready-to-use sterile surgical dressings. In 2023, the firm spun off its consumer healthcare business segment into a new publicly traded entity, Kenvue, allowing it to concentrate solely on the development and manufacturing of pharmaceutical prescription drugs and medical device technologies.
Johnson & Johnson is recognized as one of the most valuable companies worldwide and is one of only two U.S.-based corporations possessing a prime credit rating of AAA.
Analyst Rating
Johnson & Johnson News
China Adds Eli Lilly and Pfizer to Its First Private Insurance List — Is This a Buying Opportunity for Biotech Investors?
TradingKey - China officially unveiled its first list of innovative drugs covered by commercial health insurance on December 7, greenlighting 19 high-priced therapies previously excluded from the National Reimbursement Drug List (NRDL).
What Are Defensive Stocks? Should You Buy Them Now? Are Defense Stocks Defensive?
TradingKey - Defensive stocks are seen as "safe havens" during economic downturns because their products or services maintain stable demand regardless of economic cycles. Warren Buffett’s investment success is largely attributed to his preference for defensive blue-chip stocks.
Worried About a Recession? 1 Healthcare Dividend Stock That Has Thrived In Every Market Crash
TradingKey - One of those sectors is healthcare and one of the biggest healthcare companies around is Johnson & Johnson (NYSE: JNJ), a company that also pays a decent dividend to shareholders.
Financial Indicators
EPS
Total revenue
Johnson & Johnson Info
Johnson & Johnson is an American multinational corporation specializing in pharmaceuticals, biotechnology, and medical technologies, headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange (NYSE:JNJ). Its common stock is part of the Dow Jones Industrial Average, and the company is ranked No. 42 on the 2024 Fortune 500 list of the largest corporations in the United States. In 2024, it was ranked 45th on the Forbes Global 2000 list. Johnson & Johnson employs approximately 138,000 individuals globally, led by its current chairman and CEO, Joaquin Duato.
Founded in 1886 by three brothers—Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson—the company initially focused on selling ready-to-use sterile surgical dressings. In 2023, the firm spun off its consumer healthcare business segment into a new publicly traded entity, Kenvue, allowing it to concentrate solely on the development and manufacturing of pharmaceutical prescription drugs and medical device technologies.
Johnson & Johnson is recognized as one of the most valuable companies worldwide and is one of only two U.S.-based corporations possessing a prime credit rating of AAA.
Related Instruments
Popular Symbols
